Toward eliminating HLA class i expression to generate universal cells from allogeneic donors

Blood

Volumn 122, Issue 8, 2013, Pages 1341-1349

  Torikai, Hiroki ^a   Reik, Andreas ^b   Soldner, Frank ^c   Warren, Edus H ^d   Yuen, Carrie ^a   Zhou, Yuanyue ^b   Crossland, Denise L ^a,e   Huls, Helen ^a   Littman, Nicholas ^b   Zhang, Ziying ^b   Tykodi, Scott S ^d   Kebriaei, Partow ^a   Lee, Dean A ^a,e   Miller, Jeffrey C ^b   Rebar, Edward J ^b   Holmes, Michael C ^b   Jaenisch, Rudolf ^c,f   Champlin, Richard E ^a   Gregory, Philip D ^b   Cooper, Laurence J N ^a,e  

^a UNIVERSITY OF TEXAS   (United States)

^b SANGAMO BIOSCIENCES INC   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; HLA ANTIGEN CLASS 1; DEOXYRIBONUCLEASE; ZINC FINGER PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CHROMIUM RELEASE ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN EMBRYONIC STEM CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYSIS; MOLECULAR RECOGNITION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ALLOTRANSPLANTATION; CELL DIFFERENTIATION; CELL STRAIN HEK293; CYTOLOGY; ELECTROPORATION; EMBRYONIC STEM CELL; GENE TRANSFER; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PROTEIN ENGINEERING; STEM CELL TRANSPLANTATION;

ANTIGENS, CD19; BASE SEQUENCE; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DEOXYRIBONUCLEASES; ELECTROPORATION; EMBRYONIC STEM CELLS; GENE TRANSFER TECHNIQUES; HEK293 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; ZINC FINGERS;

EID: 84886849781     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-478255     Document Type: Article

References (49)

1. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
4. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010; 363(4):355-364.
5. Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med. 2010;363(2):147-155.
6. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345(25): 1794-1800.
7. Opelz G, Wujciak T, Döhler B, Scherer S, Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet. 1999;1(3):334-342.
8. Früh K, Ahn K, Peterson PA. Inhibition of MHC class I antigen presentation by viral proteins. J Mol Med (Berl). 1997;75(1):18-27.
9. Berger C, Xuereb S, Johnson DC, Watanabe KS, Kiem HP, Greenberg PD, Riddell SR. Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(1) cytotoxic T lymphocytes. J Virol. 2000;74(10):4465-4473.
10. Riolobos L, Hirata RK, Turtle CJ, et al. HLA engineering of human pluripotent stem cells. Mol Ther. 2013;21(6):1232-1241.
11. Figueiredo C, Seltsam A, Blasczyk R. Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. J Mol Med (Berl). 2006;84(5):425-437.
12. Gonzalez S, Castanotto D, Li H, et al. Amplification of RNAi-targeting HLA mRNAs. Mol Ther. 2005;11(5):811-818.
13. Haga K, Lemp NA, Logg CR, et al. Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: Averting cytotoxicity by alloreactive T lymphocytes. Transplant Proc. 2006;38(10):3184-3188.
14. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4(6):565-571.
15. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9): 636-646.
16. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD41 T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008;26(7):808-816.
17. O'Connor CM, Sheppard S, Hartline CA, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012;2:249.
18. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010; 21(4):427-437.
19. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008; 68(8):2961-2971.
20. Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimericantigen- receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24): 5697-5705.
21. Doyon Y, Choi VM, Xia DF, Vo TD, Gregory PD, Holmes MC. Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat Methods. 2010;7(6):459-460.
22. Guschin DY, Waite AJ, Katibah GE, Miller JC, Holmes MC, Rebar EJ. A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol. 2010;649:247-256.
23. Lengner CJ, Gimelbrant AA, Erwin JA, et al. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell. 2010;141(5):872-883.
24. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009;136(5):964-977.
25. Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell. 2008;3(3):346-353.
26. Johnson DR. Locus-specific constitutive and cytokine-induced HLA class I gene expression. J Immunol. 2003;170(4):1894-1902.
27. Mori M, Beatty PG, Graves M, Boucher KM, Milford EL. HLA gene and haplotype frequencies in the North American population: The National Marrow Donor Program Donor Registry. Transplantation. 1997;64(7):1017-1027.
28. Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. 2007; 25(7):778-785.
29. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035-1044.
30. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012; 23(5):444-450.
31. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood. 2012;119(12): 2709-2720.
32. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
33. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
34. Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18(5):807-815.
35. Singh H, Figliola MJ, Dawson MJ, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011; 71(10):3516-3527.
36. Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA. 2002;99(15):9864-9869.
37. Brower RC, England R, Takeshita T, Kozlowski S, Margulies DH, Berzofsky JA, Delisi C. Minimal requirements for peptide mediated activation of CD81 CTL. Mol Immunol. 1994;31(16): 1285-1293.
38. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol. 2007;7(12): 942-953.
39. Cooper LJ, Jena B, Bollard CM. Good T cells for bad B cells. Blood. 2012;119(12):2700-2702.
40. Liu PQ, Chan EM, Cost GJ, et al. Generation of a triple-gene knockout mammalian cell line using engineered zinc-finger nucleases. Biotechnol Bioeng. 2010;106(1):97-105.
41. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474(7350):212-215.
42. Katagiri T, Sato-Otsubo A, Kashiwase K, et al; Japan Marrow Donor Program. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011; 118(25):6601-6609.
43. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201-214.
44. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequencederived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187(5):813-818.
45. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669): 795-799.
46. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 2001;13(2): 193-201.
47. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: Is HLA-G the public ligand for natural killer cell inhibitory receptors?. Proc Natl Acad Sci USA. 1997;94(10):5249-5254.
48. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood. 2006;107(9):3779-3786.
49. Tykodi SS, Fujii N, Vigneron N, et al. C19orf48 encodes a minor histocompatibility antigen recognized by CD81 cytotoxic T cells from renal cell carcinoma patients. Clin Cancer Res. 2008; 14(16):5260-5269.